Notably, JNK3 was detected in the cerebrospinal fluid (CSF) of AD patients, and its increased level is statistically correlated with the rate of cognitive decline, indicating that JNK3 is a key player in this disease, which makes JNK3 an attractive CNS drug target [37,38]. The gene discussed is MAPK10; the disease is Alzheimer disease.